Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers
2010 (English)In: Journal of Proteomics, ISSN 1876-7737, Vol. 73, no 6, 1117-1132 p.Article in journal (Refereed) Published
Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab.
Place, publisher, year, edition, pages
2010. Vol. 73, no 6, 1117-1132 p.
Multiple sclerosis, CSF, Proteomics, Biomarkers, Prognosis, Treatment
IdentifiersURN: urn:nbn:se:uu:diva-136893DOI: 10.1016/j.jprot.2010.01.004ISI: 000277763800009OAI: oai:DiVA.org:uu-136893DiVA: diva2:377758